Loading clinical trials...

A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA | Clinical Trials | Clareo Health

NOT_YET_RECRUITING

A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA

A Prospective, Multicenter, Observational Cohort Study on the Efficacy and Safety of Biological Agents in Patients With Allergic Bronchopulmonary Aspergillosis

NCT07362693•Qianfoshan Hospital

View on ClinicalTrials.gov

Summary

To evaluate the efficacy and safety of biological agents in patients with allergic bronchopulmonary aspergillosis.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Meet the diagnostic criteria of allergic bronchopulmonary aspergillosis, according to the ISHAM guidelines for the diagnosis and treatment of allergic bronchopulmonary aspergillosis (2024 revision).
•2. The underlying disease was bronchial asthma, and it was severe bronchial asthma.
•3. Have had an acute asthma attack in the past year. Acute exacerbation of asthma is defined as the sudden onset of wheezing, shortness of breath, cough, chest tightness and other symptoms beyond the definition of uncontrolled asthma, or the aggravation of the original symptoms, and is characterized by decreased expiratory flow, often induced by exposure to allergens, irritants or respiratory tract infection.
•4. Blood eosinophil count ≥150 cells /μL.
•5. Age ≥ 18 years old.

Exclusion Criteria

•1. The underlying diseases were chronic obstructive pulmonary disease and bronchiectasis;
•2. Known allergic history to biological agents;
•3. Human immunodeficiency virus infection, active pulmonary tuberculosis or pulmonary malignant tumor;
•4. Complicated with other diseases requiring long-term systemic use of glucocorticoids or immunosuppressants (such as autoimmune diseases);
•5. Pregnant or lactating women;
•6. Currently participating in other interventional clinical research;
•7. Any other conditions considered by the investigator to preclude participation in the study (e.g., nonadherence, predicted survival \<1 year, or severe mental illness that prevented cooperation).

Locations (1)

Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China

Jinan, Shandong, China

Key Dates

Start Date

December 31, 2025

Primary Completion Date

December 31, 2028

Completion Date

December 31, 2028

Last Updated

January 23, 2026

Enrollment

ESTIMATED participants

Conditions

ABPABiologicsAllergic Bronchopulmonary Aspergillosis (ABPA)Cohort StudyAllergic Bronchopulmonary AspergillosisEfficacy and Safety

Interventions

Biologic Agent

DRUG

Contacts

Qian Qi, Dr.

CONTACT

+86 13706380314 qiqianqlh@163.com

Biologics for Stricturing Crohn's Diseases

NCT05645055

The Efficacy of Biologics for Stricturing Crohn's Diseases

View study

NOT_YET_RECRUITING

Predicting Biologic Therapy Success in Ulcerative Colitis Using Intestinal Ultrasound and Fat Assessment

NCT07126015

Predicting Biologics Success Via VAT Assessment

View study

TERMINATEDPHASE2

Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 23, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions